



NOTICE OF NEW PRESCRIPTION DRUG PURSUANT TO 18 V.S.A. § 4637(B)

TO: Office of the Attorney General of Vermont
AGO.highcostprescriptiondrugs@vermont.gov

FROM: Karyopharm Therapeutics Inc.

DATE: July 3, 2019

As required by 18 V.S.A. § 4637(b), Karyopharm Therapeutics Inc. is providing notice of the introduction of a new prescription drug with a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program as set forth below:

Product	NDC
XPOVIO™ (selinexor) 60mg (12 Tablets)	72237-101-01
XPOVIO™ (selinexor) 80mg (16 Tablets)	72237-101-02
XPOVIO™ (selinexor) 160mg (32 Tablets)	72237-101-04
XPOVIO™ (selinexor) 100mg (20 Tablets)	72237-101-05

85 Wells Avenue
Suite 210
Newton, MA 02459

www.karyopharm.com